Enhertu Enters India: AstraZeneca Pharma Wins Permission to Import Game-Changing Cancer Therapy

AstraZeneca Pharma India Limited has secured official permission from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Enhertu (Trastuzumab Deruxtecan 100mg/5ml vial lyophilized powder) in India for an additional cancer indication. This new approval broadens access to this critical treatment option for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors, who have previously undergone systemic therapies and lack satisfactory alternatives.

 

Key Highlights:

 

Source: Reuters, Pharmabiz

 

Source: Reuters, PharmabizAstraZeneca Pharma India Limited has secured official permission from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Enhertu (Trastuzumab Deruxtecan 100mg/5ml vial lyophilized powder) in India for an additional cancer indication. This new approval broadens access to this critical treatment option for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors, who have previously undergone systemic therapies and lack satisfactory alternatives.

 

Key Highlights:

- Permission covers the import and sale of Enhertu specifically for treating adults with advanced HER2-positive solid tumors.

- Enhertu is an antibody-drug conjugate, offering a novel mechanism for targeting and destroying cancer cells.

- The approval marks a significant expansion in AstraZeneca India’s oncology portfolio, potentially improving outcomes for patients with difficult-to-treat tumors.

- Commercial launch is subject to further statutory clearances.

- This move enhances AstraZeneca’s market presence in India’s oncology segment, reflecting a commitment to addressing unmet medical needs.

 

Source: Reuters, Pharmabiz